Persistence of subsyndromal residual symptoms after remission of major depression in patients without cardiovascular disease may condition maintenance of elevated platelet factor 4 and β-thromboglobulin plasma levels

Chiaie, Roberto Delle; Capra, E; Salviati, Massimo; Trabucchi, Guido; Pancheri, Corinna; Corrado, Alessandra; Biondi, Massimo

doi:10.1016/j.jad.2013.03.017

Cited by 8 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, depression can elevate the expression of integrin aIIb-b3 and increase plasma levels of platelet activation markers, such as platelet factor-4 (PF-4), b-thromboglobulin (b-TG), and Pselectin, ultimately enhancing platelet activity. A study demonstrated significantly higher levels of platelet activation markers, including PF-4 and b-TG, in patients with both CHD and depression compared to patients with CHD alone and healthy controls (54). Platelet activation not only fosters endothelial damage by interacting with leukocytes but also stimulates the release of related factors, further promoting the development of atherosclerosis.…”

Section: Platelet Activation and 5-hydroxytryptaminementioning

confidence: 99%

Depression and coronary heart disease: mechanisms, interventions, and treatments

Xu,

Zhai,

Shi

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

Coronary heart disease (CHD), a cardiovascular condition that poses a significant threat to human health and life, has imposed a substantial economic burden on the world. However, in contrast to conventional risk factors, depression emerges as a novel and independent risk factor for CHD. This condition impacts the onset and progression of CHD and elevates the risk of adverse cardiovascular prognostic events in those already affected by CHD. As a result, depression has garnered increasing global attention. Despite this growing awareness, the specific mechanisms through which depression contributes to the development of CHD remain unclear. Existing research suggests that depression primarily influences the inflammatory response, Hypothalamic-pituitary-adrenocortical axis (HPA) and Autonomic Nervous System (ANS) dysfunction, platelet activation, endothelial dysfunction, lipid metabolism disorders, and genetics, all of which play pivotal roles in CHD development. Furthermore, the effectiveness and safety of antidepressant treatment in CHD patients with comorbid depression and its potential impact on the prognosis of CHD patients have become subjects of controversy. Further investigation is warranted to address these unresolved questions.

show abstract

Section: Platelet Activation and 5-hydroxytryptaminementioning

confidence: 99%

Depression and coronary heart disease: mechanisms, interventions, and treatments

Xu,

Zhai,

Shi

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Forty seven of the 89 were observational studies (Azuma et al, 2011;Bär et al, 2010;Bayless et al, 2010;Beall et al, 2012;Bersani et al, 2014;Bilgen et al, 2014;Burgese & Bassitt, 2015;Casarotto et al, 2013;Chiaie et al, 2013;Dannlowski et al, 2013;Dukart et al, 2014;Ebert et al, 2010;Galletly, Paterson, & Burton, 2012;Goto et al, 2012;Guloksuz et al, 2015;Hu et al, 2010;Johansson, Ehnvall, Friberg, & Myredal, 2010;Joshi et al, 2015;Kalogerakou et al, 2015;Kautto et al, 2015;Lin et al, 2013;Loo, Mahon, Katalinic, Lyndon, & Hadzi-Pavlovic, 2011;Lucca et al, 2010;Lyden et al, 2014;McCall et al, 2013;Medda et al, 2014;Meeter, Murre, Janssen, Birkenhager, & van den Broek, 2011;Minelli et al, 2014;Nickl-Jockschat et al, 2015;Nordanskog, Larsson, Larsson, & Johanson, 2014;Ota et al, 2015;Oudega et al, 2011;Perrin et al, 2012;Piccinni et al, 2013;Rapinesi et al, 2015;Rapinesi et al, 2013;Royster et al, 2012;Saijo et al, 2010;Samuelsson, Gerdin, Öllinger, & Vrethem, 2012;Tendolkar et al, ...…”

Section: Focus and Design Of The 91 Studiesmentioning

confidence: 99%

Is Electroconvulsive Therapy for Depression More Effective Than Placebo? A Systematic Review of Studies Since 2009

Read

Arnold

2017

Ethical Hum Psychol Psychiatry

View full text Add to dashboard Cite

Is electroconvulsive therapy for depression more effective than placebo? A systematic review of studies since 2009. ABSTRACTBackground: A 2010 review of studies and previous reviews and meta-analyses found minimal evidence that ECT for depression was more effective than placebo during the treatment period and no evidence at all of efficacy beyond the end of treatment. The current review explored whether any contradictory evidence has since been generated. Method: MEDLINE and PsycINFO were searched to identify all post 2009 studies that had compared ECT and simulated ECT for depression, or had in any other way generated valid depression data for ECT recipients at two or more points in time. Results: Ninety-one studies met inclusion criteria. There were no new placebo-controlled trials. There have now been no such studies since 1985. Only four placebo-controlled studies have ever produced data beyond the end of treatment, none of which had found any advantage for ECT over placebo. Of the 91 studies only two aimed to evaluate the efficacy of ECT. Both were severely flawed. None of the other 89 produced robust evidence that ECT is effective for depression, primarily because at least 60% maintained ECT participants on medication and 89% produced no meaningful follow up data beyond the end of treatment. No studies investigated whether ECT prevents suicide. Conclusions: There is still no evidence that ECT is more effective than placebo for depression reduction or suicide prevention. Given the 1 well-documented high risk of persistent memory dysfunction, the cost-benefit analysis for ECT remains so poor that its use cannot be scientifically, or ethically, justified.

show abstract

Acute Settings and Conditions: Intensive Care Unit, Heart Disease, Stroke, Seizures

Leigh

2014

Handbook of Consultation-Liaison Psychiatry

View full text Add to dashboard Cite

Persistence of subsyndromal residual symptoms after remission of major depression in patients without cardiovascular disease may condition maintenance of elevated platelet factor 4 and β-thromboglobulin plasma levels

Cited by 8 publications

References 28 publications

Depression and coronary heart disease: mechanisms, interventions, and treatments

Depression and coronary heart disease: mechanisms, interventions, and treatments

Is Electroconvulsive Therapy for Depression More Effective Than Placebo? A Systematic Review of Studies Since 2009

Acute Settings and Conditions: Intensive Care Unit, Heart Disease, Stroke, Seizures

Contact Info

Product

Resources

About